Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODM-109 in ALS (LEVALS)
NCT02487407Phase 2Completed
- Sponsor
- Orion Corporation
- Start
- Jul 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of levosimendan in amyotrophic lateral sclerosis (ALS), sponsored by Orion Corporation. Started Jul 2015; status: completed.
02
Drugs
levosimendan
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02487407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02487407.